STAT+: A rival goes after Ocular Therapeutix on eve of pivotal readout on eye treatment
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
Ocular Therapeutix and Eyepoint Pharmaceuticals are developing competing treatments for wet age-related macular degeneration, a common cause of vision loss in older people. Their CEOs don\u2019t particularly like each other. So, with Ocular in a self-imposed quiet period ahead of a crucial clinical trial readout, Eyepoint\u2019s CEO has been doing a lot of trash talking, trying to sink investor confidence in his rival.\u00a0<\/p>\n
At an investor conference in Puerto Rico at the end of January, Jay Duker, Eyepoint\u2019s CEO, expressed doubts about Ocular\u2019s drug, called Axpaxli, and questioned why Ocular management was taking so long to announce results from its Phase 3 study, according to several people with knowledge of Duker\u2019s comments.\u00a0<\/p>\n
One conference attendee told me Duker\u2019s comments were made without evidence, but his insinuation was crystal clear: Ocular\u2019s management team was already in possession of results from the Axpaxli study, called SOL-1, but was delaying a public announcement because the data were negative.\u00a0<\/p>\n
Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n